Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sichuan Deebio Pharmaceutical Co. Ltd.
WARNING LETTER
•Sichuan Deebio Pharmaceutical Co. Ltd.•September 8, 2023

Sichuan Deebio Pharmaceutical Co. Ltd. – FDA Warning Letter, Sep 8, 2023

Record Details

The FDA inspected Sichuan Deebio Pharmaceutical Co. Ltd. in China from September 4-8, 2023, revealing significant Current Good Manufacturing Practice (CGMP) deviations for active pharmaceutical ingredients (API), rendering them adulterated under 21 U.S.C. 351(a)(2)(B). Key violations included the failure to follow and document laboratory controls contemporaneously, specifically concerning microbiological plate readings where personnel admitted to relying on memory. The firm's quality unit also failed to exercise its responsibility to ensure API compliance with CGMP, demonstrating deficiencies in investigations and document control. Overall, the firm's quality systems were deemed inadequate, and its quality system did not adequately ensure data accuracy and integrity. The company's initial response was insufficient, lacking details on retrospective reviews of documentation and investigations. The FDA acknowledged the firm's commitment to suspend production of (b)(4), USP API for the U.S. market and strongly recommended engaging a qualified CGMP consultant. The firm must provide a written response within 15 working days detailing corrective actions, with potential consequences including import alerts and refusal of new application approvals if deficiencies are not fully addressed.

Company
Sichuan Deebio Pharmaceutical Co. Ltd.
Inspection date
September 8, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · c5c9fa2c-31a9-4234-a02e-42b2d1be9ef4

Violation Codes6
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sichuan Deebio Pharmaceutical Co. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.